Cattani, Vitória Berg http://orcid.org/0000-0002-8148-403X
Jalil, Emilia Moreira http://orcid.org/0000-0001-6017-5660
Eksterman, Leonardo
Torres, Thiago http://orcid.org/0000-0002-2557-601X
Wagner Cardoso, Sandra http://orcid.org/0000-0001-5230-0003
Castro, Cristiane R. V. http://orcid.org/0000-0001-5767-1452
Monteiro, Laylla http://orcid.org/0000-0003-4907-0459
Wilson, Erin http://orcid.org/0000-0002-0237-495X
Bushman, Lane
Anderson, Peter http://orcid.org/0000-0002-1200-8494
Veloso, Valdilea Gonçalves http://orcid.org/0000-0002-6622-3165
Grinsztejn, Beatriz http://orcid.org/0000-0003-3692-5155
Estrela, Rita http://orcid.org/0000-0002-5653-1690
Hoagland, Brenda
Moura, Isabele
Waite, Daniel M. McMahon
Vieira, Desirée
Granjeiro, José Roberto
Freitas, Josias
Santos, Toni
Fernandes, Nilo
Nazer, Sandro
Marins, Luana M. S.
Ribeiro, Valéria R. T.
Silva, Robson P. N.
Costa, Giovanna G.
Vieira, Ana Carolina
Bastos, Renata A
Alves, Aline
Krstic, Tania
Ferreira, Ana Cristina G.
Derrico, Monica
Kamel, Luciana
Jalil, Cristina M.
Netto, Eduardo Carvalheira
de Sousa, Marcos Davi G.
Leite, Pedro
Mattos, Kim Geraldo
Felix, Jessica Bezerra
Baião, Tamires Vilela
Hottz, Gisele
Maia, Natália Gomes
da Silva, Tamiris Paixão
Ramos, Michelle
Porto, Tiago
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions
https://doi.org/10.1007/s40262-023-01248-0
Funding for this research was provided by:
Brazilian Ministry of Health (#01/2013 BRA/K57)
Secretaria de Vigilância em Saúde (#281/2013)
Article History
Accepted: 29 March 2023
First Online: 1 June 2023
Declarations
:
: This work was supported by the Brazilian Ministry of Health (Brasília, Brazil; #01/2013 BRA/K57), <i>Secretaria de Vigilância em Saúde</i> (SVS; #281/2013), and partially supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—CAPES—Finance Code 001. Gilead Sciences donated the study drug and covered costs related to drug concentration assessment, but had no role in study design, collection, analysis, and interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication.
: Peter Anderson has received consulting fees from Gilead, Merck, and ViiV, and research funding paid to his institution from Gilead. All other authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. It was approved by the Evandro Chagas National Institute of Infectious Diseases-FIOCRUZ Institutional Review Board. The PrEParadas study is registered with clinicaltrials.gov (NCT03220152). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: Data are available from the corresponding author upon request.
: Not applicable.
: EMJ, VGV, BG and RE conceived the study and interpreted the findings. EMJ, BG, RE and VBC drafted the manuscript. VBC did the statistical analyses with aid from EMJ and RE. TT, SWC, LE, CRVC and LM helped with data acquisition, interpretation of the findings, and drafting the manuscript. VGV, PA, LB and EW were involved in revising the manuscript for important intellectual content. All authors read and approved the final manuscript.